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Background: Subjective experience of illness affects outcomes among populations with bipolar disorder (BD). This cross-sectional
study combined qualitative and quantitative approaches to evaluate perceived treatment effects, concerns and expectations among
90 individuals with BD.
Methods: Adults with Type I BD, mean age 36.6 years, 51% women, completed a semi-structured interview that was audio taped,
transcribed, coded and analyzed along emergent themes. Quantitative scales measured depressive symptoms (Hamilton Depression Scale/
HAM-D), psychopathology (Clinical Global Impression/CGI), and insight and treatment attitudes (Insight and Treatment Attitudes
Questionnaire/ITAQ).
Results: Individuals hadmoderate depression and psychopathologywith good insight into need for treatment.Drug treatmentwas perceived
as beneficial, by “stabilizing” or “balancing” mood (42%, N=38), decreasing anxiety/depressive symptoms (19%, N=17) and improving
sleep (10%,N=9). While 39%, (N=35) of individuals denied medication concerns, nearly 29%, (N=26) feared possible long-term effects,
particularly diabetes or liver/kidney damage. Media stories and advertisements contributed to medication fears. Hopes and expectations for
treatment ranged from those that were symptom or functional status-based, such as desiring mood stabilization and elimination of specific
symptoms (23%, N=21), to more global hopes such as “being normal” (20%, N=18) or “cured” (18%, N=16).
Limitations: Limitations include relatively small sample, lack of a comparator, inclusion of only depressed individuals and those
willing to discuss their illness experience.
Conclusions: While individuals with BD appreciate the effects of medications, concerns regarding adverse effects and discrepancy
between actual and hoped-for outcomes can be substantial. Subjective experience with medications using qualitative and
quantitative methods should be explored in order to optimize treatment collaboration and outcomes.
© 2008 Elsevier B.V. All rights reserved.Keywords: Bipolar disorder; Subjective experience; Mood stabilizer; Qualitative analysis; Patient-centered treatment☆ Portions of this data were presented at the American Psychiatric Association (APA) annual meeting on May 5, 2008 in Washington D.C. and the
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0165-0327/$ - see front matter © 2008 Elsevier B.V. All rights reserved.
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While recent years have seen a proliferation of
effective treatments for Bipolar Disorder (BD), residual
symptoms and illness relapse remain all too common
(American Psychiatric Association, 2002). It is perhaps
not surprising that many patients become frustrated with
treatment, and treatment non-adherence is known to occur
in approximately 40% of individuals with BD (Lingam
and Scott, 2002). A number of theoretical models have
been developed to explain an individual's response to
illness (Becker andMaimon, 1975; Leventhal et al., 1984;
Horne, 2003), with most generally putting heavy
emphasis on how the individuals cognitively and
emotionally interpret illness, and the costs and benefits
of treatment. Research in the area of chronic illnesses,
including BD, have demonstrated that how individuals
perceive illness and treatment is important in shaping
illness behavior (Scott and Pope, 2002).
Mixed-methodologies utilizing qualitative, narrative
techniques combined with traditional quantitative methods
more typically seen in experimental medicine, in which
data on human beings is condensed to averages or
numerical statistics, have gained increasing acceptance
among social scientists (Sherman and Strang, 2004). A
limited but growing literature suggests that patient-focused,
qualitative methods can add valuable insights on patient
beliefs about BD treatment (Clatworthy et al., 2007).
The current study was a cross-sectional, exploratory,
pooled, quantitative and qualitative analysis to evaluate
attitudes and perceptions of medication treatment
among 90 individuals with BD. Specific topics
evaluated were perceived effects of medications, fears
or concerns regarding possible medication effects, and
perceived best-case hopes/expectations of what medica-
tions might do for individuals with BD.
2. Methods
This analysis pooled data from three research studies by
this group of investigators (Study 1/K-23National Institute
of Mental Health (NIMH)MH065599 PI Sajatovic, Study
2/Ohio Department of Mental Health (ODMH), 06.1223
PI Sajatovic, Study 3/Fairview Lutheran Hospital Founda-
tion PI Muzina) all using the same semi-structured
qualitative instrument, the Subjective Experience of
Medication Interview (SEMI, Jenkins et al., 2005), in a
population of patients with Type I BD and similar
inclusion/exclusion criteria. Study 1 comprised 40 out-
patients with Type I rapid cycling BD, index depressive
episode, receiving care in an Academic Medical Center
Mood Disorders Clinic (N=20) and a Community MentalHealth Clinic (CMHC) (N=20). Study 2 comprised 30
stabilized Type I BD State Hospital inpatients with index
depressive episode or mixed/depressive episode, and
Study 3 comprised 20 individuals with Type I BD, index
depressive episode, age 18–40, receiving care at a private
Regional Hospital/clinic. In addition to requiring Type I
bipolarity, index depressive episode (except for the 30-
patient State Hospital sample which allowed individuals
with mixed/depressive symptoms), inclusion criteria
included treatment with mood stabilizing medication
(lithium, anticonvulsants or maintenance antipsychotics)
for at least six months, and illness duration of at least two
years. The goal of each of the three studies was to evaluate
subjective illness experience, along multiple domains, and
across a wide range of individuals with BD using a semi-
structured qualitative instrument.
In order to obtain a broad representation of “real
world” patients with BD, exclusion criteria were minimal
and included only inability to participate in assessments or
inability to provide written, informed consent to study
participation. Individuals were enrolled following either
self-referral in response to posted study advertisement for
outpatients or referral from clinic staff in both inpatient
and outpatient samples. All studies were approved by the
appropriate local Institutional Review Boards (IRB).
Diagnostic status was confirmed using the MINI
International Neuropsychiatric Interview (MINI; Shee-
han et al., 1998). Depressive symptoms and global
psychopathology were evaluated with the 17-item
Hamilton Depression Rating Scale (HAM-D-17)
(Hamilton, 1960), and the Clinical Global Impression
(CGI) (Guy, 1976), respectively. Insight into illness was
evaluated with the Insight and Treatment Attitudes
Questionnaire (ITAQ) (McEvoy et al., 1981).
Qualitative assessment consisted of the Subjective
Experience of Medication Interview (SEMI); a semi-
structured ethnographic evaluation of subjective experi-
ence of mental illness (Jenkins et al., 2005) modified for
use with BD (Sajatovic, in press). Illness experience
domains assessed included illness attitudes, attributions
and behaviors, social relations, treatment history and
medication experience, self-medication, quality of life,
stigma, culture/ethnicity, and healthcare logistics. For this
analysis there were three primary assessments of interest
based upon specific questions in the SEMI: 1.) “What do
you think these medications are doing for you?” 2.) “Do
you have any worries or concerns about being on the
medications?” and, 3.) “What do you most want your
medications to do for you?” The SEMI was transcribed
from the audiotapes in its entirety and entered into a
software program, Atlas.ti (Scientific Software Develop-
ment, 1997), to code and analyze qualitative data
Table 1
Demographic and clinical characteristics of 90 individuals with bipolar disorder (BD).
Academic Mood Disorders
Clinic
Community Mental Health
Clinic
State Hospital Regional
Hospital
All individuals
with BD
N=20 N=20 N=30 N=20 N=90
Age — mean (SD), range n=20 n=20 n=30 n=20 n=90
41.7 (13.05),
20–62
36.35 (10.66),
20–53
36.13 (10.03),
18–55
32.12 (9.67),
18–53
36.53 (11.13),
18–62
Gender — n (%) n=20 n=20 n=30 n=20 n=90
Male 10 (50%) 10 (50%) 17 (56.7%) 9 (45%) 46 (51.1%)
Female 10 (50%) 10 (50%) 13 (43.3%) 11 (55%) 44 (48.9%)
Ethnicity — n (%) n=20 n=20 n=30 n=20 n=90
African-American 1 (5%) 5 (25%) 7 (23.3%) 1 (5%) 14 (15.6%)
Euro-American 19 (95%) 9 (45%) 19 (63.3%) 19 (95%) 66 (73.3%)
Other 0 (0%) 6 (30%) 4 (13.3%) 0 (0%) 10 (11.1%)
Education in years— mean (SD),
range
n=20 n=20 n=30 n=18 n=88
15.1 (2.36),
12–18
13.55 (1.63),
12–17
11.9 (2.28),
8–18
13.83 (2.46),
8–18
13.4 (2.49),
8–18
Age of illness onset— mean (SD),
range
n=20 n=20 n/a a n/a a n=40
29.35 (11.95),
11–46
23.55 (9.25),
5–43
26.45 (10.95),
5–46
HAM-D-17— mean (SD), range n=20 n=20 n=30 n=20 n=90
19.4 (5.22),
10–31
23.95 (5.44),
13–35
18.67 (5.24),
10–27
19.05 (6.85),
2–34
20.09 (5.96),
2–35
CGI — mean (SD), range n=20 n=19 n=30 n=20 n=89
4.3 (0.80),
3–6
5.05 (0.78),
4–6
4.67 (0.71),
3–6
4.05 (0.76),
3–6
4.53 (0.83),
3–6
ITAQ — mean (SD), range n=20 n=20 n=30 n=19 n=89
21.05 (2.11),
15–22
19.4 (2.04),
15–22
19.23 (4.80),
2–-22
21.37 (1.12),
18–22
20.13 (3.26),
2–22
HAM-D-17: Seventeen-item Hamilton Depression Scale, CGI: Clinical Global Impression, ITAQ: Insight and Treatment Attitudes Questionnaire.
a Data on Age of Illness Onset was not collected from participants in the State Hospital and the Regional Hospital.
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into discrete themes and evaluated across participants for
each thematic domain.
3. Results
3.1. Quantitative findings
Table 1 illustrates demographic and clinical char-
acteristics of the study sample. Mean age of the group
was 36.5 years, SD=11.1, range 18–62 years. The
sample was nearly evenly split between men and
women. Mean age of BD onset was 26.5 years,
SD=11.0, range 5–46 years. The majority (N=66,
73%) were Euro-American, while approximately 16%
(N=14) were African-Americans. Mean years of
education was 13.4 years, SD= 12.5, range 8–
18 years. Overall, the group was moderately depressed
with HAM-D-17 mean scores of 20.1, SD=6.0, range
2–35. Mean ITAQ scores for the entire group of
participants was 20.1, SD=3.4, range 2–22, indicating
relatively high levels of insight into illness andtreatment. Scores on the quantitative measures gener-
ally agreed with qualitative findings in that depressive
themes prevailed, and individuals felt that medication
treatment for their BD was indicated. Pharmacologic
treatments consisted of lithium in 29 (32%) of patients,
anticonvulsants in 60 (67%) of patients, antipsychotics
in 50 (56%) of patients, and antidepressants in 44 (49%)
of patients. Most individuals, 74 (82%), were on some
combination of bipolar medications.
3.2. Qualitative findings
3.2.1. Perceived effects of medications
Forty-two percent (N=38) perceived medications as
having a “stabilizing” or “balancing” effect (Table 2). The
second most common effect (19%, N=17), was a noted
decrease in depression/crying or decrease in anxiety.
Beyond these two main perceived effects of medications,
less commonly reported effects included non-specific
benefit/general mood improvement, improved sleep and
improved ability to calm down or relax. Approximately
8% of individuals specifically noted no effects.
Table 2
Perceived effects of medications among 90 individuals with bipolar disorder.
Perceived effect Academic
Clinic
CMHC State
Hospital
Regional
Hospital
All Representative quotes
N=20 N=20 N=30 N=20 N=90
Stabilization/balancing effect 6 (30%) 10 (50%) 11 (37%) 11 (55%) 38 (42%) “They get me more level”
Decrease depression/
anxiety/crying
4 (20%) 4 (20%) 5 (17%) 4 (20%) 17 (19%) “They help me so I'm not so sad,
depressed, withdrawn”
Non-specific benefit/ general
mood improvement
1 (5%) 3 (15%) 4 (13%) 1 (5%) 9 (10%) “It seemed like my mood was getting better”
Improved sleep 2 (10%) 3 (15%) 4 (13%) 0 (0%) 9 (10%) “They're making me more able to get sleep”
Calm down/relax 3 (15%) 2 (10%) 3 (10%) 0 (0%) 8 (9%) “They keep me calm…to a point”
No effect 3 (15%) 2 (10%) 1 (3%) 1 (5%) 7 (8%) “I really don't see a change”
Side effects: sedation, tremor,
weight gain
1 (5%) 0 (0%) 3 (10%) 1 (5%) 5 (6%) “My legs shake”
Reducing hallucinations 0 (0%) 1 (5%) 3 (10%) 1 (5%) 5 (6%) “Stops all the voices”
Reduces mania 0 (0%) 1 (5%) 1 (3%) 1 (5%) 3 (3%) “It helps prevent the mania”
Affects brain chemicals 1 (5%) 1 (5%) 0 (0%) 1 (5%) 3 (3%) “It has something to do with the chemical in my
brain—a re-uptake inhibitor”
Decrease suicidal thoughts 1 (5%) 0 (0%) 1 (3%) 0 (0%) 2 (2%) “They got me out of the suicidal depression”
Decrease irritability 2 (10%) 0 (0%) 0 (0%) 0 (0%) 2 (2%) “I'm less irritable—I have some patience”
Feel numb/anesthetized 0 (0%) 1 (5%) 0 (0%) 1 (5%) 2 (2%) “Anesthetizing me”
Improved coping/feel normal 1 (5%) 0 (0%) 1 (3%) 0 (0%) 2 (2%) “They're helping me cope better”
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medications
Over 1/3 of individuals (39%, N=35) reported no
concerns with medication (Table 3). A number
expressed the notion that they had been taking
medications for a long time and had not personally
experienced problems with medication, and this largely
determined their future concerns or fears. However,
29% of individuals did have specific concerns about
medications, predominantly focusing on fear of devel-
oping new diseases such as diabetes or organ damage,Table 3
Expressed fears or concerns regarding medication treatment among 90 indiv
Expressed fear/worry Academic
Clinic
CMHC State
Hospital
R
H
N=20 N=20 N=30 N
No concerns 8 (40%) 5 (25%) 16 (53%) 6
Concern about possible medical adverse
effects/organ damage/new disease
production
5 (25%) 8 (40%) 8 (27%) 5
Not wanting to take medication rest of
life/worry of addiction
1 (5%) 1 (5%) 1 (3%) 2
Ineffectiveness/loss of effectiveness 0 (0%) 0 (0%) 1 (3%) 3
Costs 1 (5%) 1 (5%) 1 (3%) 0
Forgetting to take or overdosing 1 (5%) 1 (5%) 0 (0%) 0
Being forced to take medication/doctor
will make prescribing error
0 (0%) 2 (10%) 0 (0%) 0such as liver or kidney failure. Individuals volunteered
the fact that their fears were often fueled by media
reports of adverse effects and law suits regarding
medication adverse effects. Some individuals cited
examples of legal firms that advertised on the television
or radio soliciting calls by individuals who had been
treated with atypical antipsychotic medications in
particular. Fear of having to take medication long-term
or becoming addicted to medication was expressed by
only a minority (6%, N=5). Concern about costs of
medications was expressed by 5% or fewer individuals.iduals with bipolar disorder.
egional
ospital
All Representative quote
=20 N=90
(30%) 35 (39%) “I've been on it for 8 years now—it's OK”
(25%) 26 (29%) “I just want to make sure it doesn't do any liver
damage or any kind of damage to internal organs”
(10%) 5 (6%) “I'll get addicted”
(15%) 4 (4%) “It might not work at all”
(0%) 3 (3%) “I don't have any health insurance…. and I
wouldn't be able to get my prescriptions filled”
(0%) 2 (2%) “I might forget medications when I go on
vacation”
(0%) 2 (2%) “My being forced to take it”
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medications
The most commonly expressed hope/expectation
(23%, N=21) concerning what medications could or
might be able to do for the entire group of individuals with
BD was to reduce symptoms and balance mood.
Individuals were keenly aware of the effects of mood
cycling/“ups and downs” and the destructive outcomes of
these mood swings and depressive/manic states. A
number of individuals (20%, N=18) expressed the desire
to be “normal” or “average” as opposed to being a self-
identified personwithBD.Nearly 20% (N=16) expressed
the wish to be “cured” of BD while at the same time
expressing their disappointment that current medication
treatment had not achieved a “cure” for them. Themes of
loss and a desire to have these losses somehow restored
were expressed by some individuals with BD, including
hope for repair of relationships with family members, re-
building of self-esteem, or restoration of material losses
such as a house or car. Some individuals (8%, N=7)
volunteered humorous answers to this query stating that
they would like to have super powers or some other
attribute from medication, usually accompanied by
another more realistic hope. Finally, the desire to
experience a manic state was expressed by only a small
minority of individuals with BD (3%).
4. Discussion
This mixed-methods analysis of medication treat-
ment perceptions, concerns and hopes/expectations for
treatment among 90 individuals with BD demonstrates
surprisingly consistent responses among groups of
individuals from diverse treatment settings. Based
upon the results of quantitative psychiatric rating scales,
individuals in this sample all had substantial bipolar
depressive symptoms and moderately severe global
psychopathology in spite of being prescribed medica-
tion to treat their BD. Along with extant symptoms,
individuals generally had excellent insight into their
illness, positive attitudes towards treatment and gen-
erally felt that medication treatments were indicated and
necessary. Qualitative analysis expanded views on the
specific value that individuals with BD attributed to
their medications, comfort level with potential side
effects and hopes for illness outcome resulting from
medication treatments that individuals may or may not
have articulated to their clinicians.
Individuals with BD generally perceived benefit from
drug treatment, primarily in the form of “stabilizing” or
“balancing” mood (42%, N=38), decreased anxiety/
depressive symptoms (19%, N=17) and improved sleep(10%, N=9). Perceived efficacy thus appeared to be pre-
dominantly focused on achieving level/euthymic mood
and combating depressive symptoms. Anti-manic efficacy
was not generally cited as a dominant perceived effect,
possibly because this sample was, by study inclusion
criteria, experiencing depressive symptoms. While the
earliest and largest number of randomized controlled trials
(RCTs) of BD treatments have evaluated the anti-manic
activity of various pharmacotherapies (Smith et al., 2007),
themost salient issue for individuals strugglingwith bipolar
symptoms in the sample reported here appears to be efficacy
of treatments for bipolar depression. A recent patient-
preference analysis of 469 individuals with BD similarly
suggested that patients prioritized reduction of depression
severity over mania severity (Johnson et al., 2007). Inter-
ventions intended to promote treatment adherence in
individuals with BD should emphasize the potential for
mood stabilizing drugs to prevent depressive episodes as an
issue that is particularly relevant to patients. This may be a
critical focus for BD-specific psychotherapies.
Individuals receiving treatment for bipolar disorder
acknowledged efficacy on mood symptoms while
tempering this with reports of side effects and concerns
about future medical comorbidity related to medication
treatments. While many (39%, N=35) individuals
denied specific concerns regarding medication treat-
ments, nearly 29% (N=26) expressed fears over
possible long-term side effects, particularly diabetes or
liver/kidney damage. Individuals cited media stories and
advertisements that elicited fears regarding possible
risks with atypical antipsychotic medications. Our
findings support that of Scott and Pope (2002) who
studied individual's attitudes and concerns regarding
bipolar treatments, and found that fear of side effects
might actually be a stronger predictor for medication
adherence than the actual experienced side effects.
Understanding concerns that have been expressed by
others, including family, friends or the media as they
relate to an individual's past treatment, current condi-
tion, and future worries is thus a critical component of
assessing satisfaction or acceptance with medication
therapy and optimizing future adherence.
Hopes and expectations for bipolar medication treat-
ment in the sample studied here ranged from a symptom
or functional status basis, such as desiring mood
stabilization and elimination of specific symptoms
(23%, N=21), to more global hopes such as “being
normal” (20%, N=18) or having their illness “cured”
(18%, N=16). Individuals in this study frequently noted
that no one had previously asked them extensively about
their own feeling about their illness and treatment and that
the types of questions asked in the qualitative assessment
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tions such as psychoeducation, which has been demon-
strated to have utility in improving treatment adherence in
populations with BD (Rouget and Aubry, 2007), may
assist patients and families in understanding the limita-
tions of medication treatments as well as their strengths,
and may be particularly critical in public mental health
care settings where discrepancy between what individuals
hope to see with medications and what is actually
achieved can be substantial.
The findings from this study should be interpreted in
the light of a number of limitations including the
relatively small sample size (although thematic satura-
tion appeared to have been achieved), lack of a
comparison group, and the fact that all of the individuals
with BD in these studies were willing to participate in
research. As confirmed by the quantitative ITAQ results,
most participants in this report were relatively insightful
regarding their illness and treatment. This may have lead
to a bias of overrepresentation by individuals who have
positive attitudes towards treatment and medication.
Additionally, individuals in this study all had depressive
symptoms, and thus the results cannot necessarily be
extrapolated to populations who are experiencing either
euthymia or predominantly manic symptoms.
5. Conclusions
While individuals with BD appreciate the mood-
stabilizing and anti-depressant effects of medications,
concerns regarding long-term adverse effects and
discrepancy between actual effects of medications and
hoped for outcomes can be substantial. Subjective
experience with medications, and mixed methodologies
that combine qualitative and quantitative assessments
should be further explored in order to optimize treatment
collaboration and outcomes.
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